342,594 Shares in Amgen Inc. $AMGN Acquired by PFA Pension Forsikringsaktieselskab

PFA Pension Forsikringsaktieselskab purchased a new position in Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, Holdings Channel reports. The fund purchased 342,594 shares of the medical research company’s stock, valued at approximately $112,607,000.

A number of other institutional investors also recently added to or reduced their stakes in AMGN. Board of the Pension Protection Fund purchased a new position in Amgen in the fourth quarter worth approximately $26,000. Olistico Wealth LLC purchased a new stake in shares of Amgen during the 4th quarter worth approximately $33,000. Cloud Capital Management LLC purchased a new stake in shares of Amgen during the 3rd quarter worth approximately $34,000. Ares Financial Consulting LLC purchased a new stake in shares of Amgen during the 4th quarter worth approximately $34,000. Finally, Saranac Partners Ltd purchased a new stake in shares of Amgen during the 3rd quarter worth approximately $37,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Price Performance

Shares of AMGN opened at $329.82 on Friday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The firm has a 50-day simple moving average of $358.07 and a 200-day simple moving average of $340.45. The company has a market capitalization of $178.00 billion, a price-to-earnings ratio of 23.18, a price-to-earnings-growth ratio of 3.42 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 139.90% and a net margin of 20.96%.The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 22.16 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 3.1%. The ex-dividend date is Friday, May 15th. Amgen’s payout ratio is 70.84%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on AMGN. Leerink Partners restated a “market perform” rating and set a $355.00 price objective on shares of Amgen in a research report on Thursday, March 5th. Barclays began coverage on shares of Amgen in a research report on Friday, February 20th. They set an “equal weight” rating and a $350.00 price objective for the company. Daiwa Securities Group boosted their price objective on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Royal Bank Of Canada boosted their price objective on shares of Amgen from $360.00 to $370.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Finally, UBS Group boosted their price objective on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $357.54.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen’s Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.